January 31st, 2014
A (Not So) New Drug Landscape for Pulmonary Arterial Hypertension
John Ryan, MD
John Ryan offers a primer on three newly approved drugs for pulmonary arterial hypertension.
March 25th, 2013
Once Again FDA Rejects Oral Treprostinil for Pulmonary Arterial Hypertension
Larry Husten, PHD
For the second time the FDA has issued a complete response letter rejecting the new drug application (NDA) of oral treprostinil for the treatment of pulmonary arterial hypertension (PAH). The manufacturer of the drug, United Therapeutics, said in a press release that it planned to discuss the decision with the FDA. “We remain confident that oral treprostinil will play […]
NEJM Journal Watch — Recent Cardiology Articles- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?
- A Randomized Trial of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation
- An Early Look at a Novel Intranasal Loop Diuretic